Keyphrases
Bioresponsive
100%
Microbicide Delivery
100%
Combination Microbicide
100%
Delivery System
100%
HIV Transmission
100%
Primate Model
50%
HIV Infection
50%
Microbicides
50%
Cellulose Acetate Phthalate
33%
Acyclovir
33%
Tenofovir
33%
Herpes Simplex Virus 2 (HSV-2)
33%
Aggravating Factors
16%
Neutralizing Agent
16%
Virus Neutralization
16%
Female-to-male
16%
HIV-1 Acquisition
16%
Infected Population
16%
Virus Diseases
16%
Anti-HIV Microbicide
16%
Vaginal pH
16%
Antiviral nucleoside
16%
Frequency-duration
16%
Virus Shedding
16%
Simian HIV
16%
Dose Duration
16%
Herpes Simplex Virus Type 2 Infection
16%
HSV Infection
16%
Nucleoside Inhibitors
16%
Macaque
16%
Fold Increase
16%
Viral Co-infection
16%
Rhesus Macaque Model
16%
Viral
16%
High Incidence
16%
Preventive Measures
16%
HIV Patients
16%
Self-assembling
16%
Antiviral Activity
16%
Toxicity in Vitro
16%
Dose Rate
16%
Health Problems
16%
Release Rate
16%
Rate of Increase
16%
Disease Development
16%
Dose-response
16%
Staggering
16%
Epidemiological Study
16%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Bioresponsive
100%
Antimicrobial Agent
100%
Herpes Simplex Virus 2
27%
Human Immunodeficiency Virus Infection
27%
Infection
27%
Prevalence
18%
Aciclovir
18%
Cellacefate
18%
Antivirus Agent
18%
Tenofovir
18%
Anti-Human Immunodeficiency Virus
9%
In Vitro Toxicity
9%
Macaca
9%
Rhesus Monkey
9%
Antiviral Activity
9%
Mixed Infection
9%
Disease Course
9%
Nucleoside
9%
Diseases
9%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Antimicrobial Agent
100%
Human Immunodeficiency Virus Infection
27%
Herpes Simplex Virus 2
27%
Prevalence
18%
Tenofovir
18%
Coinfection
9%
Viral Shedding
9%
Human Immunodeficiency Virus 1
9%
Dose Response
9%
Vagina pH
9%
Virus Neutralization
9%
Rhesus Monkey
9%
Macaca
9%
Antiviral Activity
9%